Pluviaendo Visuals Pluviaendo Visuals

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Aurigene Pharmaceutical Services","sponsor":"PENAO Pty Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beroni Initiates Manufacture of its Novel, Potential Anti-Cancer Drug PENAO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for PENAO

    Menu

    PENAO

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Aurigene Pharmaceutical Services

              Contact Supplier
              • Deals
              Virtual BoothAurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.
              Contact Supplier Contact Supplier
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Beroni Initiates Manufacture of its Novel, Potential Anti-Cancer Drug PENAO

              Details:

              This next-generation adenine nucleotide translocase (ANT) inhibitor, PENAO, was shown to be safe and well-tolerated in a phase I clinical trial conducted in Australia where encouraging efficacy data was observed.

              Lead Product(s): PENAO,Sirolimus

              Therapeutic Area: Oncology Product Name: PENAO

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: PENAO Pty Ltd

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement August 18, 2021

              Aurigene company banner

              2024 ASCO Annual meeting

              Not Confirmed

              envelop Contact Supplier
              EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
              Axplora- The partner of choice for complex APIs.
              Post Enquiry
              POST ENQUIRY